Literature DB >> 22840846

Risk factors for bradycardia requiring pacemaker implantation in patients with atrial fibrillation.

Tyler W Barrett1, Robert L Abraham, Cathy A Jenkins, Stephan Russ, Alan B Storrow, Dawood Darbar.   

Abstract

Symptomatic bradycardia may complicate atrial fibrillation (AF) and necessitate a permanent pacemaker. Identifying patients at increased risk for symptomatic bradycardia may reduce associated morbidities and health care costs. The aim of this study was to investigate predictors for developing bradycardia requiring a permanent pacemaker in patients with AF. The records of all patients treated for AF or atrial flutter in an academic hospital's emergency department from August 1, 2005, to July 31, 2008, were reviewed. Survival and the presence of a pacemaker as of November 1, 2011, were determined. Cases were defined as patients with pacemakers placed for bradycardia after their AF diagnoses. Patients without pacemakers who were followed constituted the control group. Variables for the logistic regression analysis were identified a priori. A post hoc model was fit adjusting for AF type and atrioventricular nodal blocker use. Of the 362 patients in the cohort, 119 cases had permanent pacemakers implanted for bradycardia after AF diagnosis, and 243 controls were alive without pacemakers. The median follow-up time was 4.5 years (interquartile range 3.8 to 5.4). Odds ratios were determined for age at the time of AF diagnosis (1.02, 95% confidence interval [CI] 1 to 1.04), female gender (1.58, 95% CI 0.95 to 2.63), previous heart failure (2.72, 95% CI 1.47 to 5.01), and African American race (0.33, 95% CI 0.12 to 0.94). The post hoc model identified permanent AF (odds ratio 2.99, 95% CI 1.61 to 5.57) and atrioventricular nodal blocker use (odds ratio 1.43, 95% CI 0.85 to 2.4). In conclusion, in patients with AF, heart failure and permanent AF each nearly triple the odds of developing bradycardia requiring a permanent pacemaker; although not statistically significant, our results suggest that women are more likely and African Americans less likely to develop bradycardia requiring pacemaker implantation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22840846      PMCID: PMC3470776          DOI: 10.1016/j.amjcard.2012.06.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  24 in total

1.  Lenient versus strict rate control in patients with atrial fibrillation.

Authors:  Isabelle C Van Gelder; Hessel F Groenveld; Harry J G M Crijns; Ype S Tuininga; Jan G P Tijssen; A Marco Alings; Hans L Hillege; Johanna A Bergsma-Kadijk; Jan H Cornel; Otto Kamp; Raymond Tukkie; Hans A Bosker; Dirk J Van Veldhuisen; Maarten P Van den Berg
Journal:  N Engl J Med       Date:  2010-03-15       Impact factor: 91.245

Review 2.  New insights into pacemaker activity: promoting understanding of sick sinus syndrome.

Authors:  Halina Dobrzynski; Mark R Boyett; Robert H Anderson
Journal:  Circulation       Date:  2007-04-10       Impact factor: 29.690

3.  Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease.

Authors:  Michael O Sweeney; Alan J Bank; Emmanuel Nsah; Maria Koullick; Qian Cathy Zeng; Douglas Hettrick; Todd Sheldon; Gervasio A Lamas
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

4.  Pacemaker utilization during permanent atrial fibrillation in patients who received pacemaker implantation for sinus node dysfunction.

Authors:  Huagui Li; Dhanunjaya Lakkireddy; Hema Korlakunta; Karen Rovang; Tom Hee
Journal:  Am J Cardiol       Date:  2005-10-01       Impact factor: 2.778

Review 5.  Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review.

Authors:  Pasquale Santangeli; Giuseppe Ferrante; Gemma Pelargonio; Antonio Dello Russo; Michela Casella; Stefano Bartoletti; Luigi Di Biase; Filippo Crea; Andrea Natale
Journal:  Europace       Date:  2010-02-26       Impact factor: 5.214

6.  Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.

Authors:  Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2009-02-03       Impact factor: 29.690

7.  Chart reviews in emergency medicine research: Where are the methods?

Authors:  E H Gilbert; S R Lowenstein; J Koziol-McLain; D C Barta; J Steiner
Journal:  Ann Emerg Med       Date:  1996-03       Impact factor: 5.721

8.  Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation.

Authors:  Dawood Darbar; Alison A Motsinger; Marylyn D Ritchie; James V Gainer; Dan M Roden
Journal:  Heart Rhythm       Date:  2007-02-09       Impact factor: 6.343

9.  Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome.

Authors:  H R Andersen; L Thuesen; J P Bagger; T Vesterlund; P E Thomsen
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

10.  The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker.

Authors:  Alessandro Capucci; Gianluca Botto; Giulio Molon; Andrea Spampinato; Stefano Favale; Alessandro Proclemer; Antonio Porfilio; Tiziana Marotta; Marco Vimercati; Giuseppe Boriani
Journal:  Am Heart J       Date:  2008-06-09       Impact factor: 4.749

View more
  8 in total

1.  Risk of emergent bradycardia associated with initiation of immediate- or slow-release metoprolol.

Authors:  Jaekyu Shin; Marco Gonzales; Mark J Pletcher
Journal:  Pharmacotherapy       Date:  2013-06-27       Impact factor: 4.705

2.  Impact of high-grade atrioventricular block and cumulative frequent pacing on atrial arrhythmias.

Authors:  Eisha Wali; Amrish Deshmukh; Abdallah Bukari; Michael Broman; Zaid Aziz; Andrew Beaser; Gaurav Upadhyay; Hemal M Nayak; Roderick Tung; Cevher Ozcan
Journal:  Pacing Clin Electrophysiol       Date:  2018-07-16       Impact factor: 1.976

3.  Predictors of regional variations in hospitalizations following emergency department visits for atrial fibrillation.

Authors:  Tyler W Barrett; Wesley H Self; Cathy A Jenkins; Alan B Storrow; Benjamin S Heavrin; Candace D McNaughton; Sean P Collins; Jeffrey J Goldberger
Journal:  Am J Cardiol       Date:  2013-08-22       Impact factor: 2.778

4.  Heart rate determines the beneficial effects of beta-blockers on cardiovascular outcomes in patients with heart failure and atrial fibrillation.

Authors:  Athanasius Wrin Hudoyo; Hiroki Fukuda; Miki Imazu; Kazuhiro Shindo; Haiying Fu; Yuko Iwata; Shin Ito; Masafumi Kitakaze
Journal:  Hypertens Res       Date:  2019-06-18       Impact factor: 3.872

5.  Patients with atrial fibrillation and permanent pacemaker: Temporal changes in patient characteristics and pharmacotherapy.

Authors:  Frederik Dalgaard; Martin H Ruwald; Tommi Bo Lindhardt; Gunnar H Gislason; Christian Torp-Pedersen; Jannik L Pallisgaard
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

6.  The Absence of Atrial Contraction as a Predictor of Permanent Pacemaker Implantation after Maze Procedure with Cryoablation.

Authors:  Chang-Seok Jeon; Man-Shik Shim; Seung-Jung Park; Dong Seop Jeong; Kyoung-Min Park; Young Keun On; June Soo Kim; Pyo Won Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-06-05

7.  Risk factors and a 3-month risk score for predicting pacemaker implantation in patients with atrial fibrillations.

Authors:  Frederik Dalgaard; Jannik Langtved Pallisgaard; Tommi Bo Lindhardt; Gunnar Gislason; Paul Blanche; Christian Torp-Pedersen; Martin H Ruwald
Journal:  Open Heart       Date:  2020-03-24

8.  Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial.

Authors:  William T Abraham; Jonathan P Piccini; Christopher Dufton; Ian A Carroll; Jeffrey S Healey; Christopher M O'Connor; Debra Marshall; Ryan Aleong; Dirk J van Veldhuisen; Michiel Rienstra; Stephen B Wilton; Michel White; William H Sauer; Inder S Anand; Sophia P Huebler; Stuart J Connolly; Michael R Bristow
Journal:  Heart Rhythm O2       Date:  2021-11-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.